Sutro Biopharma Company Leadership

Sutro Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.258) % which means that it has lost $0.258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (18.1001) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 5th of January 2026, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to drop to -0.88. At this time, Sutro Biopharma's Other Current Assets are very stable compared to the past year. As of the 5th of January 2026, Debt To Assets is likely to grow to 0.50, while Total Assets are likely to drop about 304.3 M. As of the 5th of January 2026, Common Stock Shares Outstanding is likely to drop to about 8.3 M. In addition to that, Net Loss is likely to grow to about (101.9 M)Sutro Biopharma shows a total of 85.14 Million outstanding shares. Over half of Sutro Biopharma's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Sutro Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Sutro Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Sutro Biopharma Workforce Comparison

The company has Profit Margin (PM) of (2.05) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (4.01) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $4.01.

Sutro Biopharma Insider Trading History

Sutro Biopharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Sutro Biopharma often depends on how effective the management is. Sutro Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sutro management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sutro management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.